
August 30, 2014	Web Version \| Share with a colleague \| eNews Subscribe	You are subscribed to the FormularyWatch eNews

Single-tablet HIV drug approved by FDA

FDA has approved abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg (Triumeq, ViiV Healthcare) as as a first-line therapy to treat HIV.
» Read more about Triumeq

FDA approves apixaban for treatment of DVT, PE

FDA has approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE.
» Read more about Eliquis

#icymi